HTD Biosystems Inc.

High Throughput Development of Pharmaceuticals

HomeAbout usServicesContact usUpcoming EventsLyophilizationPublicationsTech transferOur CustomersExp. DesignBiochemical AnalysisCase study 1Case study 2Case study 3Case study 4Case study 5Solid-state structureJOBS

SELECTED PUBLICATIONS

  1. Lackowski N. P., Pitzer J. E., Tobias, M., Van Rheen, Z.; Nayar, R.; Mosharraf, M.; Stringer, K. A. Safety of Prolonged, Repeated Administration of a Pulmonary Formulation of Tissue Plasminogen Activator in Mice. Accepted for publication in Pulmonary Pharmacology and Therapeutics, Oct 2009.
  2. Stringer, K.A., Meghan, D., John, S., Campos, J., Van Rheen, Z., Mosharraf, M., and Nayar, R. Accelerated dosing frequency of pulmonary formulation of tissue plasminogen activators is well-tolerated in mice, Clinical and Experimental Pharmacology and Physiology, 35 (2008) 1454-1460.
  3. Mosharraf, M., Malmberg , M., and Fransson, J.,  Formulation, lyophilization and solid-state properties of a pegylated protein. International Journal of Pharmaceutics, 336 (2007) 21 
  4. Mosharraf, M., Assessment of degree of disorder (amorphicity) of lyophilized formulations of Growth Hormmone using Isothermal Microcalorimetry. J Drug Dev Ind Pharm.,30, 461-472, 2004.
  5. Katayama, D.S., Nayar, R., Chou, D.K., Valente, J.J., Cooper, J., Henry, C.S., Vander Velde, D.G., Villarete, L., Liu, C.P., Manning, M.C. Effect of buffer species on the thermally induced aggregation of interferon-tau,(2006) J. of Pharm. Sci., 95 (6), pp. 1212-1226.
  6. Katayama, D.S., Nayar, R., Chou, D.K., Campos, J., Cooper, J., Vander Velde, D.G., Villarete, L., Liu, C.P., Manning, M.C., Solution behavior of a novel type 1 interferon, interferon-tau;(2005) J. of Pharm. Sci., 94 (12), pp. 2703-2715.
  7. Bai, S., Nayar, R., Carpenter, J. F., Manning, M.C., Noninvasive determination of protein conformation in the solid state using near infrared (NIR) spectroscopy, J. Pharm. Sci. 2005, 94, 2030-8.
  8. Dunn, J. S., Nayar, R., Campos, J., Hybertson, B. M., Zhou, Y., Manning, M. C., Repine, J. E., and Stringer, K. A., Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery. Pharm. Res., Vol. 22, No. 10, Oct 2005.
  9. Dunn, J. S., Nayar, R., Campos, J., Hybertson, B. M., Zhou, Y., Manning, M. C., Repine, J. E., and Stringer, K. A., Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery. Pharm. Res., Vol. 22, No. 10, Oct 2005.
  10. Mosharraf, M. and Nystrom, C., The apparent solubility of drugs in partially crystalline systems, J. Drug Dev. Ind. Pharm., 2003, 29, 603-622
  11. Mosharraf. M and Nystrom. C., The effect of particle size and shape on the surface specific dissolution rate of microsized, practically insoluble drugs, Int. J. Pharm. 122 (1995) 35-47.
  12. Mosharraf, M. K.M. G. Taylor and D. Q. M. Craig., Effect of calcium ions on the surface charge and aggregation of Phosphatidyl-choline liposomes, J. Drug Target., 2 (1995) 541-545.

BOOK/ BOOK CHAPTER

  1. Mosharraf, M., The Effects of Solid State Properties on Solubility and In Vitro Dissolution Behaviour of Suspended Sparingly Soluble Drugs. Acta Universitatis Upsaliensis, Reprocentralen, Uppsala, 1999, IBSN 91-554-4474-1.
  2. Nayar, R., Manning, M.C., "High throughput formulation: strategies for rapid development of stable protein products" in Rational Design of Stable Protein Formulations, Theory and Practice., Edt by Carpenter, J. and Manning, M., 2002, Pharmaceutical biotechnology, Vol 13, Kluwer Academic/ Plenum Publishers, New York, pp. 177-198.
  3. Nayar, R., Schroit, A.J., Fidler, I.J., "Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties" in Methods in Enzymology, Vol. 132,1986 , pp. 594-603.